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Edited by Pe´ter FriedrichAbstract Transglutaminase 2 (TG2), a multifunctional enzyme
with Ca2+-dependent protein crosslinking activity and GTP-
dependent G protein functions, is often upregulated in cells
undergoing apoptosis. In cultured cells TG2 may exert both
pro- and anti-apoptotic eﬀects depending upon the type of cell,
the kind of death stimuli, the intracellular localization of the en-
zyme and the type of its activities switched on. The majority of
data support the notion that transamidation by TG2 can both
facilitate and inhibit apoptosis, while the GTP-bound form of
the enzyme generally protects cells against death. In vivo studies
conﬁrm the Janus face of TG2 in the initiation of the apoptotic
program. In addition, they reveal a further role: the prevention of
inﬂammation, tissue injury and autoimmunity once the apoptosis
has already been initiated. This function of TG2 is partially
achieved by being expressed and activated also in macrophages
digesting apoptotic cells and mediating a crosstalk between dying
and phagocytic cells.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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During the last 15 years tremendous progress has been made
in revealing the molecular mechanisms of apoptosis and other
forms of natural cell death. It became evident that there are
multiple pathways that mediate either death or survival of cells
with the participation of pro- and anti-apoptotic protein fam-
ilies, such as caspase, Bcl-2 and death receptor proteins. How-
ever, members of either of these families may mediate opposite
eﬀects: e.g., some caspases are not only killer enzymes but may
mediate cell proliferation as well [1], Bax, Bak and BH3-only
proteins of the Bcl-2 survival protein family initiate apoptosis
[2], while triggering the Fas death receptors can also promote
proliferation [3].Abbreviations: EGF, epidermal growth factor; HPR, N-(hydroxyphe-
nyl)retinamide; Rb, retinoblastoma protein; TG, transglutaminase;
TGFb, tumor growth factor b
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doi:10.1016/j.febslet.2005.03.063Transglutaminase 2 (TG2) is a unique member of an enzyme
family (EC 2.3.3.13) because in addition to its primary enzy-
matic activity of Ca2+-dependent transamidation of polypep-
tide chains through their glutamine and lysine residues (or
through polyamines), it also binds GTP (which blocks transa-
midation) and may act as a G protein. In addition, it also has a
protein disulﬁde isomerase activity and may function even as a
protein kinase [4–7]. Besides acting intracellularly, TG2 can
also be secreted by unidentiﬁed mechanisms into the cellular
environment, where it may participate in cell adhesion pro-
cesses and stabilization of the extracellular matrix [8].
Some years ago we have described that TG2/tissue transglu-
taminase is induced and activated in cells undergoing apopto-
sis in the liver and thymus forming highly cross-linked protein
polymers and proteinaceous shells which were resistant to
detergents as well as chaotropic agents and could be isolated
from tissues [9,10]. We postulated that transamidation activity
of TG2 may be one of the mediators or facilitators of apopto-
sis, and may contribute to the stabilization of dying cells.
[11,12]. While several additional data have provided further
evidence for a pro-apoptotic activity of TG2, recent results
have raised the possibility also for a survival role. Can these
seemingly contradictory sets of data be reconciled?2. Pro-apoptotic functions of TG2
Accumulation of TG2 in various cells undergoing apoptosis
upon divergent stimuli has been demonstrated both in vivo
and under cell culture conditions [13–15]. The induction of
the enzyme may be mediated through various nuclear recep-
tors and response elements including retinoids and tumor
growth factor b (TGFb) [16–18]. Since cell penetrating speciﬁc
inhibitors of transglutaminases were not available, alternative
approaches had to be used to clarify the role of TG2 in the
apoptosis process. In U937 cells overexpression of the enzyme
primed cells for suicide, while by inhibiting its expression using
anti-sense transglutaminase constructs the rate of apoptosis
could be signiﬁcantly reduced [19]. Similarly, overexpression
of TG2 in neuroblastoma cells resulted in a 4–5-fold more ra-
pid death as compared to the wild-type cells [20]. This sug-
gested a direct role of the enzyme in the death program.
Using cell permeable synthetic substrates it was also demon-
strated that in HL-60 and U937 cells the enzyme could tran-
samidate the actin and retinoblastoma (Rb) proteins
following the initiation of apoptosis [21,22]. However, in our
yet unpublished experiments an active site mutant of TG2
could also promote cell death in these cells suggesting thatblished by Elsevier B.V. All rights reserved.
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the apoptosis induction. One possible mechanism is the induc-
tion of death through the recently described BH3 domain of
TG2 [23]. Cell permeable peptides mimicking this domain
(but not its mutants forms) could induce conformational
change and translocation of Bax to the mitochondria, release
of cytochrome c and death of neuroblastoma cells. In addition,
Bax acted as a substrate of TG2 at the mitochondrial level.
Based on these results Piacentini and his co-workers have pro-
posed an interaction between TG2 and Bax through their BH3
domains. A TG2-dependent polymerization of Bax may occur
when the level of Ca2+ is increased at the mitochondrial level
during the course of apoptosis. The covalent polymerization
resulted may then stabilize the pore-forming and cytochrome
c-releasing conformation of Bax. Clearly, this puts TG2 onto
the stage of upstream regulatory players of the mitochondrial
apoptosis pathway. It remains to be seen, however, how gen-
eral this phenomenon is in terms of cell types and apoptotic
signaling pathways.
In the late phase of apoptosis dropping of the normally high
intracellular GTP concentration (which blocks transamidating
activity of TG2) and the overall elevation of Ca2+ levels result
in extensive protein cross-linking and formation of detergent
insoluble protein scaﬀolds in cells containing high levels of
TG2 [10]. Similar observations were made when TG2 contain-
ing cells were exposed to stimuli leading to loss of Ca2+
homeostasis and consequent necrosis [24]. TG2-dependent
crosslinking stabilizes the dying cells before their clearance,
inhibits leakage of intracellular components and may prevent
scarring and inﬂammation [11,25].3. TG2 may protect against apoptosis
Adhesion-dependent survival signaling of cells is mainly
mediated by the adhesive glycoprotein ﬁbronectin binding to
cell-surface matrix receptors (primarily the a5b1 integrins)
through their Arg-Gly-Asp (RGD) sites. Synthetic RGD pep-
tides inhibit this binding leading to detachment-induced apop-
tosis called anoikis. Griﬃn and his co-workers [26] have
described a novel RGD-independent cell adhesion mechanism
of osteoblasts and ﬁbroblasts that rescues cells from anoikis in-
duced by blocking the RGD-dependent survival signaling.
This newly proposed pathway is mediated by externalized
TG2 bound to ﬁbronectin and cell surface heparan sulfate
chains, is integrin-independent, requires the function of pro-
tein kinase Ca and leads to activation of Rho and the focal
adhesion kinase. Cell adhesion to TG2- ﬁbronectin does not
require the transamidating activity of the enzyme, though at
the high calcium concentration of the extracellular space
TG2 is very likely in the active conformation [27].
According to Aeschlimann et al. [28] TG2 can also promote
cell adhesion by regulating and being regulated by phospholi-
pase C through binding to it with the non-transamidating GTP
form of the enzyme [29]. This pathway also involves protein ki-
nase Ca, Rho and focal adhesion kinase, but the mechanism is
independent of the externalization and binding of TG2 to
ﬁbronectin. Therefore, it is still an open question how TG2
is involved in the extracellular matrix-dependent cells survival
mechanism.
Cerione and his co-workers [30] have recently shown that in
some cell lines treated with retinoic acid the retinoic acid-induced TG2 can protect also against apoptosis induced by
the synthetic retinoid N-(hydroxyphenyl)retinamide (HPR).
Phosphoinositide 3-kinase activity was required for both the
retinoic acid-stimulated expression and GTP-binding activity
of TG2 [31], while its induction was antagonized by the Ras-
ERK pathway [32]. GTPase activity of TG2 was found suﬃ-
cient to protect cells from HPR-induced death suggesting that
the survival signaling does not require transamidating activity
of TG2 [30]. On the other hand, in their next set of experiments
it was shown that TG2 protects Rb from caspase-induced deg-
radation in a transamidation dependent manner [33], and sug-
gested that transamidation of Rb by TG2 is necessary for its
ability to inhibit apoptosis. This apparent controversy may
arise from the use of monodansylcadaverine which is a com-
petitive but non-speciﬁc inhibitor of transglutaminases and is
known to accumulate in membrane structures. Therefore,
without direct demonstration of in situ changes in protein
transamidation the use of monodansylcadaverine by itself is
not suﬃcient to prove that the observed eﬀect is linked to
transamidation function of TG2.
In breast cancer cell lines epidermal growth factor (EGF)
could inhibit doxorubicin-induced apoptosis while upregulated
TG2 [34]. Expression of exogenous TG2 could mimic the sur-
vival advantage of EGF. In addition, the observation that
transfection of cells with transamidation-defective TG2 before
EGF treament could block the death-preventing eﬀect of EGF
argued for the role of transaminidation in the protection
against death.4. What determines the diﬀerential eﬀect of TG2 on cell fate?
The above results clearly suggest that TG2 has the capability
both to facilitate and to prevent apoptosis. These two oppos-
ing activities may be separated in the sense that each occurs
distinctly depending on the speciﬁc biochemical pathways of
apoptosis in diﬀerent cell types, the kind of stimuli, the intra-
cellular localization of the enzyme and the type of activity of
TG2 switched on. It has been proposed that the observed
upregulation of TG2 in some cells dying by apoptosis upon
distinct stimuli is a cellular regulatory mechanism to block
or delay the onset of death rather than reﬂecting a direct par-
ticipation of the enzyme in apoptosis [33]. On the other hand,
the BH3 domain of TG2 can clearly mediate cell death at the
mitochondrial level in other types of cells. TG2–Bax interac-
tion might be anti-apoptotic at ﬁrst by blocking Bax action
on the mitochondria and preventing cytochrome c release
[23]. After apoptosis induction, however, the calcium-activated
TG2 polymerizes Bax to a pore-forming complex. Alterna-
tively, it cannot be excluded that the TG2–Bax complex is al-
ready proapoptotic similarly to other BH3-only proteins
without transamidating activity, and transamidation results
only in further stabilization of the proapoptotic conformation.
It has also been shown that TG2 modulates apoptosis in a
stimulus-dependent manner [35]. It potentiates apoptosis in re-
sponse to osmotic stress with increased in situ transamidating
activity, and protects cells against heat shock-induced apopto-
sis without increased transamidation, very likely acting as a G
protein.
Johnson and her co-workers [36] have designed experiments
to see how the intracellular localization and transamidating
activity of TG2 modulates its eﬀect on thapsigargin-induced
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ants targeting diﬀerent cellular compartments and it was found
that cytosolic TG2 was pro-apoptotic by virtue of its transam-
idating activity. On the other hand, its nuclear localization
attenuated apoptosis in human embryonic kidney cells without
a requirement for transamidation but being dependent on a
non-covalent interaction between TG2 and Rb as opposed to
the need of transamidation of RB to protect human promyelo-
cytic leukemia cells [33].
Secreted TG2 can protect cells from anoikis in an RGD
independent manner without a requirement for the G protein
or the transamidating activity [26]. Regarding transamidation
and G protein function the so far published data show that
the G form of the enzyme has not been found proapoptotic
in any system while its transamidating activity was more often
required for facilitating cell death than for survival. One can-
not exclude the possibility that the newly discovered biochem-
ical properties of TG2, namely its protein disulﬁde isomerase
and protein kinase activity [6,7], are also important in deter-
mining how TG2 inﬂuences cell death.5. Messages from the living tissues
All the results discussed in the above sections have been ob-
tained from cell culture experiments, and it is still a question,
how relevant these data are to the in vivo settings. TG2 knock
out mice have been developed in two laboratories [37,38], and
these animals were found viable, to grow up to normal size and
weight with no apparent abnormalities in organ functions
including the extracellular matrix or the heart (where the need
for its G protein function has been most expected). Cells taken
from these animals did not show any defect in apoptosis in
either way, that is they were not less or not more resistant to
death stimuli than their normal counterpart. Certainly, these
observations may question both the pro-apoptotic and pro-
survival function of TG2. One explanation may be the
possibility that induction of other transglutaminases my com-
pensate for the loss of TG2 in these mice, as we also found
induction of TG1, 3, 5 and 7, in addition to TG2, in the thy-
mus following injection of various apoptotic stimuli (our yet
unpublished observation). Alternatively, for the in vivo induc-
tion of TG2 in apoptotic cells the tissue environment is also re-
quired, as we did not ﬁnd induction of TG2 in apoptotic
thymocytes under in vitro conditions, while it was highly ele-
vated in vivo [39,18]. The lack of TG2 induction in vitro might
explain while TG2+/+ and TG2/ died with similar kinetics
in vitro. In line with this possibility we found that TG2+/+ red
blood cells that express TG2 constitutively [40] expose phos-
phatidylserine, an early sign of apoptosis [41], faster than
TG2/ red blood cells if exposed to an apoptotic stimulus
implying that at least in these cells the presence of TG2 facili-
tates apoptosis-related events.
There are indirect data which suggest that transglutaminase-
mediated processes are indeed involved in the in vivo apoptosis
program. When the crosslinked apoptotic bodies are taken up
by professional or non-professional phagocytic cells and di-
gested in the lysosomes, the e(c-glutamyl)lysine crosslink
formed by transglutaminase is not digested because it is resis-
tant to proteolysis [42]. This dipeptide is released from phago-
cytes and appears in the circulation [43]. In line with the idea of
the involvement of TG2 in the in vivo apoptosis program, wedetected elevated concentrations of the dipeptide in the blood
during clearance of a high number of apoptotic cells in the thy-
mus or liver [39,43].
In correlation with these observations closer examination of
the in vivo apoptosis program of the thymus has revealed that
that thymus disappears slower in the TG2/ animals than in
their wild-type counterparts following injection of various
apoptotic stimuli [14]. Though this was partially the result of
an impaired phagocytosis of apoptotic cells, determination of
the percentage of accumulated dead and viable cells suggested
that the in vivo rate of apoptosis was also delayed. The pro-
death activity of TG2 was detected in neuronal cells as well,
where ablation of TG2 reduced autophagy type of death in a
model of Huntingtons disease [44].
The novel ﬁnding of the studies on TG2/ mice was that
while TG2 was clearly not required for the initiation of the
apoptotic program, it was required for the proper phagocyto-
sis of apoptotic cells. Though TG2 could promote phagocyto-
sis from the side of apoptotic cells by facilitating the
phosphatidylserine exposure that is required for the recogni-
tion of apoptotic cells [45], or by crosslinking the S19 ribonu-
clear protein that acts as chemotactic factor for macrophages
[46], the main defect was found in macrophages. This was par-
tially related to a defect in TGFb activation [47], as TGFb was
shown to promote phagocytosis of apoptotic cells [14,48]. In
addition, these macrophages show detectable changes also in
their cytoskeletal structure suggesting that signaling pathways
that regulate cytoskeletal rearrangement during phagocytosis
might also be aﬀected by the absence of TG2. This possibility
is under current investigation in our laboratory.
Interestingly, we found that in certain cells and conditions
TG2 can protect cells against death in vivo. Injecting anti-
Fas antibodies to study thymic apoptosis, we found that
TG2/ mice are more susceptible to Fas-induced death than
their wild-type counterparts. This was found to be related to
an impaired a1b-adrenergic signaling in the liver, in which
TG2 participates as a G protein. In hepatocytes Fas engage-
ment induces a Bid and mitochondria-dependent apoptosis
[49], and we found that the impaired a1b-adrenergic signaling
results in a decreased bcl-xL expression in these cells.
TG2/ cardiac cells were also found to be more susceptible
to ischemia reperfusion-induced injury than their wild-type
counterparts; however, this is not related to the G protein
activity of TG2 (our yet unpublished observation). In addition,
TG2/ hepatocytes were more sensitive also to carbon tetra-
chloride-induced liver injury as a result of a decreased tissue
stability and repair in the absence of TG2; these observations
were conﬁrmed by human studies as well [50].6. Participation of TG2 in the crosstalk between dying and
phagocytic cells to ensure tissue integrity
The above in vivo studies conﬁrmed the Janus face activity
of TG2 in the initiation of apoptosis. In certain cells, like thy-
mocytes, neurons or red blood cells, TG2 facilitates apoptosis.
In hepatocytes and cardiac cells it has a protective role against
induction of massive cell death. Generally, however, from the
in vivo results obtained in our laboratory we would propose
that the main role of TG2 in vivo to ensure that once apoptosis
has been initiated, it is ﬁnished without causing inﬂammation
and apparent tissue injury. There are many ways through
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sis by either direct mechanism in certain apoptotic cells
[19,20,23], or indirectly by promoting activation of TGFb re-
leased by macrophages that can promote the death of various
cells [14,51]. This ensures that all the unwanted cells are killed
and fast without leading to necrosis. In apoptotic cells TG2
also promotes the formation of chemoattractants [46] and
the exposure of phosphatidylserine that facilitate migration
of macrophages to the apoptosis site and recognition of apop-
totic cells, respectively. TG2 also participates in the activation
of TGFb which is required for the in vivo induction of TG2 in
both macrophages and apoptotic cells [14,52]. TG2-dependent
crosslinking of proteins and formation of protective protena-Fig. 1. Transglutaminase 2 expressed both in apoptotic cells and
macrophages participates in various processes that ensure the fast
recognition and removal of apoptotic cells, and prevention of the
release of harmful cellular content from the dying cells.
Fig. 2. Connection between tissue transglutaminase and TGF-b in the
regulation of apoptosis and removal of apoptotic cells in the thymus.
Recognition of apoptotic cells via phosphatidylserine receptors (PsR)
triggers latent TGF-b release and activation by the simultaneously
released TG2. Both macrophages and apoptotic cells possess TGF-b
receptors (TGF-R). In apoptotic thymocytes TGF-b promotes apop-
tosis induced by speciﬁc signals and induces TG2, while in macro-
phages TGF-b promotes phagocytosis and downregulation of the
formation of proinﬂammatory cytokines. Induction of TG2 by TGF-b
in macrophages results in an autoregulatory loop leading to further
TGF-b formation and release.ceous shells will prevent the leakage of harmful cell content
from the apoptotic cells [11], while TG2 in macrophages will
promote the speed of phagocytosis [14] and result in further
formation of TGFb (Fig. 2). In addition to promoing the rate
of apoptosis, induction of TG2 and the eﬃciency of phagocyto-
sis, TGFb was found to be essential for the proper downregula-
tion of proinﬂammatory cytokine production in macrophages
as well [53]. If, however, necrosis still occurs TG2 promotes
both tissue stability and repair [50]. In TG2/ animals all
these anti-inﬂammatory actions are compromised resulting in
the appearance of inﬂammatory cells at the apoptosic sites in
short term and leading on long term to autoimmunity [14].
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